Key Takeaways
- Informed consent is a conversation and voluntary decision supported by a signed document; a signature alone does not prove understanding.
- The current ethics-approved version should explain the purpose, experimental elements, assignment, procedures, foreseeable risks, possible benefit or no benefit, alternatives, costs, compensation and withdrawal rights.
- An international patient needs information in a language they understand. An interpreter facilitates communication; an impartial witness has a different, limited role when a participant or representative cannot read.
- Consent to treatment, trial participation, genetic testing, storage or secondary use of samples, and optional sub-studies may be separate decisions.
- New safety information or material changes may require an updated discussion and re-consent. Withdrawal stops future participation but cannot always erase data already lawfully collected.
Content
The most important part of a clinical-trial consent form is not the signature page. It is whether the patient had accurate, understandable information, enough time to ask questions, freedom from pressure, and a real choice between participation and alternatives.
China’s 2020 Good Clinical Practice (GCP) defines informed consent as a process in which a person is told the matters that may affect the decision and voluntarily agrees to participate, with a signed and dated form documenting that process [1]. The same rules place participant rights and safety ahead of scientific and social benefit.
Which document should be in front of you?
The study site should use the latest consent form approved by its ethics committee, identifiable by title, version and date. The patient and the person conducting consent sign and date it; the participant should receive a signed original or copy and the other written information provided [1]. Blank pages, missing version numbers, unexplained handwritten changes or a request to sign after trial-only procedures deserve immediate clarification.
Consent for routine medical care is not automatically consent for research. A trial may also have separate forms for optional tumour biopsy, genetic testing, long-term sample storage, future unspecified research, data transfer, pregnancy follow-up or an imaging sub-study. Ask which choices are required for the main trial and which are optional. Declining an optional sub-study should not be presented as declining all care unless the approved protocol genuinely makes that component mandatory.
What a useful consent discussion must cover
Under China’s 2020 drug GCP, participant information includes the study overview and purpose; treatment and chance of assignment; required procedures, including invasive procedures; obligations; experimental aspects; foreseeable risks and inconvenience; expected benefit and the possibility of no benefit; alternatives; treatment and compensation for trial-related injury; payment or reimbursement; expected costs; voluntariness; withdrawal; confidentiality; and contacts [1].
Do not settle for labels such as “innovative therapy” or “standard group.” Translate them into concrete facts:
- Which drug, device or procedure is experimental in each arm?
- Is assignment random, and what is the numerical chance of each arm?
- What would the patient receive outside the trial today?
- Which scans, biopsies, admissions, washouts and contraceptive rules exist only because of research?
- Which serious or common harms are known, and which remain uncertain?
- What does the study aim to learn, and is direct benefit expected, merely possible or not expected?
- Who pays for the study product, standard care, complications, travel and extended hospitalisation?
- Who answers urgent medical questions and who answers questions about participant rights?
The US FDA’s consent guidance identifies the same core distinctions among research purpose and duration, procedures, foreseeable risks, possible benefits, alternatives, confidentiality, injury arrangements, contacts and voluntary withdrawal [2]. This is useful as a reading framework, but a study conducted in China follows its approved Chinese protocol and applicable Chinese requirements.
Randomisation, placebo and therapeutic misconception
Consent should state the possibility of assignment to each arm. Randomisation means the treatment is assigned by the study method rather than selected according to the individual doctor’s ordinary treatment preference. Blinding may mean the patient, investigator or assessor does not know the assignment unless an approved unblinding condition is met.
If placebo is used, ask whether it replaces treatment or is added to standard care, what rescue treatment exists, and when treatment may change for progression or toxicity. “The doctor invited me” does not mean the investigator already knows the experimental option is better. A trial is designed precisely because an important question remains unanswered.
Language: translation is part of comprehension
The 2020 Chinese GCP requires oral and written information to use language and expressions understandable to the participant, representative and witness, and requires enough time and opportunity for questions [1]. For an international patient, ask whether the translated form itself is ethics-approved, which language version governs if wording differs, and how questions and answers will be documented.
A family member may provide emotional support but may omit, soften or misunderstand uncomfortable information. A trained medical interpreter is preferable for eligibility, risk, contraception, adverse-event and withdrawal discussions. The interpreter should translate both directions without making the decision for the patient.
An impartial witness is not simply another name for an interpreter. Under ICH E6(R3), the witness is independent of the trial and attends when the participant or legally acceptable representative cannot read, confirming that the information was accurately explained and apparently understood [3]. Whether a witness, interpreter signature or translated short form is appropriate must be determined by the site and ethics-approved process.
Voluntary choice and pressure
The investigator or delegated research staff should conduct consent without coercion or improper inducement. The patient should have adequate time unless a genuine, ethically approved emergency pathway applies. Questions may be taken away, discussed with family or an independent clinician, and brought back before signing.
Look for pressure such as “sign now or lose all medical care,” guarantees of cure, concealment of standard options, or payment presented as a reward rather than reimbursement or compensation. China’s GCP states that refusal or withdrawal should not lead to discrimination, retaliation or loss of medical treatment and rights [1].
Costs, payment and research-related injury
“The trial is free” is too vague. Separate the investigational product and research-only procedures from routine tests, standard drugs, hospital charges, travel, accommodation, visa extensions and treatment after complications. Ask who is invoiced, whether insurance is billed, which costs can change and what happens after early withdrawal.
The form should explain available treatment and compensation for trial-related harm, not promise that every medical problem during the trial will automatically qualify. Record the contact, reporting deadline, documentation required, insurance or sponsor pathway and dispute process. FDA guidance likewise treats injury treatment and compensation information as an essential element for more-than-minimal-risk research [2,4].
Samples, genetic testing and future use
A blood draw or tumour block can generate information beyond the immediate treatment decision. China’s 2023 Measures for Ethical Review of Life Science and Medical Research require consent information to address how personal data are used and shared, whether secondary use will occur, confidentiality, and—with biological samples—the type, quantity, purpose, storage, product development, sharing, secondary use, external provision and destruction [5]. China’s human genetic-resources implementing rules also require respect for privacy and written consent as applicable [6].
Ask whether testing is for trial eligibility, an exploratory endpoint or future research; whether clinically meaningful findings are returned; who can access coded data; how long specimens remain; whether samples or data may leave China; and whether future use can be declined without losing the main trial. “Anonymous” and “coded” are not identical: coded material may still be linkable through a key.
Capacity, children and representatives
If an adult lacks decision-making capacity, the authorised representative process must follow applicable law and the approved protocol. The person should still receive information and be involved to the extent they can understand. For a child, guardian permission is required and the child’s own agreement should be sought when capable; China’s 2020 GCP includes additional rules for a child who objects or later becomes able to provide consent [1].
Capacity is decision-specific and may change with delirium, sedation, neurological illness or recovery. A relative’s physical presence does not automatically establish legal authority. International families should confirm what proof of relationship or guardianship the site accepts before travel.
Withdrawal: what stops and what may remain
A participant may refuse or withdraw without punishment. Before leaving, ask what must happen safely: tapering a study drug, an end-of-treatment examination, urgent toxicity monitoring, transfer to standard care and return of devices or diaries. Agreeing to a safety visit does not cancel the withdrawal decision.
Withdrawal can involve separate choices: stop the intervention, stop in-person visits, allow remote survival follow-up, allow use of already collected data, or permit stored samples to remain. The exact limits depend on the consent, protocol and law. Data already collected and needed to preserve research integrity or safety records may not simply be deleted; the site should explain what further collection will cease and what information must be retained.
Re-consent is not clerical paperwork
China’s GCP requires important new information that may affect continued participation to be communicated and recorded, and may require the participant to sign an updated consent [1]. The 2023 ethics measures explicitly require renewed consent when participant-related research content changes materially, risk materially increases or decision-making capacity changes [5].
Examples include a newly identified serious risk, a new arm, different biopsy schedule, changed pregnancy precautions, longer follow-up or a child reaching the capacity to decide. Compare versions, ask what changed, and make a fresh decision. Prior participation does not oblige anyone to accept new conditions.
China published a revised drug GCP in June 2026 that is scheduled to replace the 2020 version on 1 September 2026 [7]. For consent occurring near that date, the site should identify the currently approved version and any transition or re-consent plan.
A signature-day check
Before signing, the patient should be able to explain in their own words:
- why the study is being done and what remains uncertain;
- what each arm receives and how assignment happens;
- which procedures and restrictions are research-specific;
- the most important risks, possible benefit and no-benefit possibility;
- reasonable alternatives outside the trial;
- costs, payments and injury arrangements;
- how data and samples will be used;
- whom to contact, how to withdraw and what follow-up remains.
If these answers are unclear, pause. A consent form can be signed later; misunderstanding cannot be repaired by adding a signature.
Medical and legal disclaimer: This guide offers general education, not legal advice or consent for a specific study. Requirements depend on the study, institution, ethics approval and applicable law. Ask the investigator and ethics committee contact about the approved documents.
FAQ
Can the coordinator ask me to sign before the doctor speaks with me?
Delegated staff may support the process, but questions involving medical judgment must be answered by qualified study personnel. Do not sign until the approved information is explained and your questions are answered.
Does signing mean I cannot leave the trial?
No. Participation remains voluntary, and you may withdraw. Ask how to stop the intervention safely and what data, samples or follow-up can or must remain after withdrawal.
Is an English translation enough for an international patient?
Only if the patient genuinely understands it and the site’s ethics-approved process supports its use. Confirm version control, interpreter support and which language controls if texts differ.
Is a family interpreter the same as an impartial witness?
No. Interpreters translate communication. An impartial witness is independent of the trial and observes consent when the participant or representative cannot read. One person should not be assumed to fill both roles automatically.
Must I agree to future genetic research to join the treatment trial?
Not necessarily. Future sample or data use may be optional, but some biomarker testing may be integral to the main protocol. Ask the site to mark which permissions are mandatory and which can be declined separately.
Sources
- National Medical Products Administration and National Health Commission of China — Good Clinical Practice for Drug Trials, 2020
- US Food and Drug Administration — Informed Consent Guidance for IRBs, Clinical Investigators and Sponsors
- International Council for Harmonisation — ICH E6(R3) Good Clinical Practice
- US Food and Drug Administration — Institutional Review Boards Frequently Asked Questions
- National Health Commission of China and Partner Ministries — Measures for Ethical Review of Life Science and Medical Research Involving Humans, 2023
- Ministry of Science and Technology of China — Implementing Rules for the Regulation on Human Genetic Resources, 2023
- Chinese National Regulators — Revised Drug GCP, Effective 1 September 2026
Image Review
- Decision: Replaced with a topic-specific ImageGen hero and visually reviewed for medical relevance, obvious generation artifacts and bilingual reuse.
- Editorial note: The existing illustration shows a reception-style conversation and a clipboard with generic icons. It has no ethics-approved consent document, trial arms, risk and alternatives discussion, signature or copy handover, so it does not depict informed consent accurately.